Please assess the completion status of the following clinical trial:

Trial Title: Safety and Clinical and Virologic Outcomes in CKD Patients Treated With Nirmatrelvir-ritonavir

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 and above.~* COVID-19 infection and symptom onset no more than 5 days, with or without prior vaccination.~* WHO CPS 1-4~* Indicated for nirmatrelvir-ritonavir treatment~Exclusion Criteria:~* Patients cannot swallow capsules or adhere to protocol.~* Severe COVID-19 disease, including patients who require oxygen supplement therapy~* Significant hypersensitivity to nirmatrelvir, ritonavir, or any component of the formulation~* Patients require co-administration of drugs that are highly dependent on CYP3A4 for clearance and cannot be omitted during the treatment period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).